Modulation of Amphetamine-Induced Dopamine Release by Group II Metabotropic Glutamate Receptor Agonist LY354740 in Non-Human Primates Studied with Positron Emission Tomography

@article{Berckel2006ModulationOA,
  title={Modulation of Amphetamine-Induced Dopamine Release by Group II Metabotropic Glutamate Receptor Agonist LY354740 in Non-Human Primates Studied with Positron Emission Tomography},
  author={Bart N. M. van Berckel and Lawrence S. Kegeles and Rikki Waterhouse and Ningning Guo and Dah-Ren Hwang and Yiyun Huang and Rajesh Narendran and R. Van Heertum and Marc Laruelle},
  journal={Neuropsychopharmacology},
  year={2006},
  volume={31},
  pages={967-977}
}
Pharmacological evidence suggests that schizophrenia is associated with increased stimulation of dopamine (DA) D2 receptors. Recently, several groups have demonstrated that amphetamine-induced DA release is increased in schizophrenia, providing direct evidence for dysregulation of DA systems in this condition. In healthy volunteers, pretreatment with the noncompetitive N-methyl-D-aspartate (NMDA) antagonist ketamine increases amphetamine-induced DA release to levels similar to those observed in… CONTINUE READING